anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
An aqueous dispersion for the production of binders or coatings for solid oral drugs having a water content of 90-40 wt. % and a solids portion of 10-60 wt. %, whereby said solids portion is composed of:(A) 10-99 wt. % of a polymer mixture consisting of:(a) 75-99 wt. % of a polymethacrylate copolymer consisting of up to 98-85 wt. % of alkyl (meth)acrylate monomers with C1-C4 alkyl residues and up to 2-15 wt. % of alkyl (meth)acrylate monomers with a quaternary ammonium group in the alkyl residue, and (b) 25-1 wt. % of an alkali salt of carboxymethylcellulose having a weight average molecular weight of less than 150,000, and(B) 90-1 wt. % of at least one substance normally added to pharmaceutical formulations.
The application relates to a heart aging biomarker and application thereof as a drug target for delaying heart aging. The examples disclose the use of MLF1 as a biomarker in peripheral blood and/or myocardial tissue. The examples disclose the use of substances which reduce the activity and/or the expression level of MLF1 in peripheral blood and/or myocardial tissue. The examples disclose the use of a substance with MLF1 as a drug target in the preparation of a product. The examples disclose the use of mice with reduced MLF1 activity and/or expression in peripheral blood and/or myocardial tissue in the preparation and/or screening of a medicament. The examples disclose products for slowing cardiomyocyte aging. The examples disclose kits of substances for detecting MLF1 activity and/or expression level.
BREYNA (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol is available in two strengths and is supplied in the following package sizes:

Dosage Forms and Strengths

Each strength is supplied as a pressurized aluminum canister with an attached counting device, a blue plastic actuator body with a blue mouthpiece, and attached grey dust cap. Each 120 inhalation canister has a net fill weight of 10.3 grams. Each canister is packaged in a foil overwrap pouch with desiccant sachet and placed into a carton. Each carton contains one canister and a Patient Information leaflet.

The BREYNA canister should only be used with the BREYNA actuator, and the BREYNA actuator should not be used with any other inhalation drug product.

The correct amount of medication in each inhalation cannot be ensured after the labeled number of inhalations from the canister have been used, even though the inhaler may not feel completely empty and may continue to operate. The inhaler should be discarded when the labeled number of inhalations have been used or within 3 months after removal from the foil pouch. Never immerse the canister into water to determine the amount remaining in the canister (“float test”).

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Store the inhaler with the mouthpiece down.

For best results, the canister should be at room temperature before use. Shake well for 5 seconds before using.

Keep out of the reach of children. Avoid spraying in eyes.

CONTENTS UNDER PRESSURE.

Do not puncture or incinerate. Do not store near heat or open flame. Exposure to temperatures over 120ºF may cause bursting. Never throw container into fire or incinerator.
Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
Asciminib is a first-in-class BCR::ABL1 inhibitor that Specifically Targets the ABL1 Myristoyl Pocket (STAMP). It is approved worldwide and in Japan for chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to previous tyrosine kinase inhibitor (TKI) therapy. In the Phase 3 ASCEMBL study, patients with CML-CP who received ≥ 2 prior ATP-competitive TKIs were randomized (2:1) to asciminib 40 mg twice-daily or bosutinib 500 mg once-daily. Here, we report the 96-week results of the subgroup analysis of Japanese patients (asciminib, n = 13; bosutinib, n = 3) in the ASCEMBL study. The MMR rate at Week 96 was 46.2% in asciminib-treated patients, increasing from Weeks 24 and 48. Patients who achieved MMR at Week 24 remained in MMR up to the Week 96 cutoff. While a high proportion of patients treated with asciminib remained on treatment at cutoff, none randomized to bosutinib were on treatment at Week 96. Despite the longer duration of exposure to asciminib, its safety and tolerability continued to be favorable with no new or worsening safety findings. Overall, the efficacy and safety outcomes in the Japanese subgroup were comparable with the ASCEMBL global study population, which supports the use of asciminib in Japanese patients with previously treated CML-CP.
This is a clinical gene transfer study that aims to verify the safety and efficacy of the use of retroviral vectors to introduce the human adenosine deaminase (ADA) gene into the hematopoietic progenitors of patients affected with severe combined immunodeficiency due to ADA deficiency. In addition, this protocol will examine the effects of the ADA gene transfer on the immune system of treated patients. Patients with ADA deficiency and ineligible for matched sibling allogeneic bone marrow transplantation are eligible to participate to the study. To increase engraftment and selective advantage of gene-corrected cells, busulfan will be used as cytoreduction agent and enzyme replacement (PEG-ADA) therapy will be discontinued. CD34+ hematopoietic progenitors will be isolated from the patient bone marrow or cord blood, exposed to retroviral vector-mediated gene transfer and reinfused into the patient through a peripheral vein. Clinical, immunological and molecular follow-up studies will assess safety, toxicity, and efficacy of the procedure.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns normalisation of the blood microvesicle level in arterial hypertension, abdominal obesity and impaired glucose tolerance. That is ensured by the administration of Irbesartan 150 mg once in the morning combined with Metformin 500 mg twice a day. In addition, the patients perform graduated physical activity, including morning hygienic gymnastics, therapeutic gymnastics and graduated physical exercises throughout a day. The length of treatment is at least 5 weeks. ^ EFFECT: method ensures the correction of the blood microvesicle level in the case patients, and consequently, reduced risk of thrombotic complications, such as infarction and stroke. ^ 1 ex
, , , , , , , , , , In patients receiving serotonin reuptake inhibitor drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serioussometimes fatalreactions including hyperthermiarigiditymyoclonusautonomic instability with possible rapid fluctuations of vital signsand mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Furthermorelimited animal data on the effects of combined use of SSRIs and MAOIs suggest that these drugs may act synergistically to elevate blood pressure and evoke behavioral excitation. Thereforeit is recommended that citalopram HBr should not be used in combination with an MAOIor within 14 days of discontinuing treatment with an MAOI. Similarlyat least 14 days should be allowed after stopping citalopram HBr before starting an MAOI.
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature].

Should freezing occur, gadobutrol injection should be brought to room temperature before use. If allowed to stand at room temperature, gadobutrol injection should return to a clear and colorless to pale yellow solution. Visually inspect gadobutrol injection for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored, if particulate matter is present or if the container appears damaged.
A method to process microalgae biomass and produce high-value chemicals from microalgae biomass is disclosed. The method uses the same biomass cells to extract more than one component such as are lipids, water-soluble chemicals, carotenoids, polysaccharides and algae meal. The method is a sequence of physical and chemical treatments. Water soluble polysaccharides produced by the method exhibit properties of low viscosity at low shear thinning. A method for extracting dietary fiber from microalgal biomass is disclosed. Compositions of water-soluble polysaccharides that are fermented slowly by colon microbiota with less gas production than commercial dietary fiber FOS are disclosed. The present inventions described herein provide a method of improving colon health by increasing butyrate during a microalgal dietary fiber fermenting process by colonic microbiota.
The invention belongs to Chinese patent drug technique field. There is no medicine treating hemorrhoid for hui nationality in current market because of their dietetic restraint. The invention provides a special medicine treating hemorrhoid containing no animal material, which is characterized by long and thorough effect, difficulty to recur, safe property, low cost, wide raw material resource and simple production process. The formulation comprises rhubarb horsetails, radix pseudostell, gentian, gentian, gleditsin (or Chinese honey locust), white atractylodes rhizome, banksia rose and plaster stone. The mentioned eight medicines are not used for treating hemorrhoid according to Tradit Chinese Medicine Dictionary and teaching materials in high college of medicine. The inventor proved after long term practice that they could treat hemorrhoid. The utilization of banksia rose is the feature of this invention. The medicine can treat internal hemorrhoid, external hemorrhoid and mixed hemorrhoid, and abnormal urination and defecation caused from hemorrhoidal bleeding and urinary tract infection.
BACKGROUND AND OBJECTIVES: Anastomotic leakage is a serious complication following surgery for cancer of the rectum. It is not clear whether reinforcing sutures could prevent anastomotic leakage. Therefore, this study aims at evaluating the efficacy of reinforcing sutures on anastomotic leakage.
METHODS: We searched PubMed, Embase, and the Cochrane Library databases from inception to January 31, 2023. We included studies comparing anastomosis with reinforcing sutures to anastomosis without reinforcing sutures after low anterior resection. Risk of bias was assessed by the Cochrane tool for RCTs and the Risk of Bias in Non-Randomized Studies (ROBINS)-I tool for observational studies. The overall quality of evidence for primary outcome was assessed using Grading of Recommendations Assessment, Development, and Evaluations methodology.
RESULTS: Two RCTs (345 patients) and four observational studies (783 patients) were included. Anastomotic leakage occurred in 4.4% (24 of 548) of patients with reinforcing sutures and 11.9% (69 of 580) of patients without reinforcing sutures. Meta-analysis showed a lower incidence of anastomotic leakage (RR, 0.41; 95% CI 0.25 to 0.66, low certainty) in patients with reinforcing sutures. Operative time (WMD, -3.66; 95% CI -18.58 to 11.25) and reoperation for anastomotic leakage (RR, 0.69; 95% CI 0.23 to 2.08) were similar between patients with reinforcing sutures and those without reinforcing sutures.
CONCLUSIONS: While observational data suggest that, there is a clear benefit in terms of reducing the risk of anastomotic leakage with the use of reinforcing sutures, RCT data are less clear. Further large, prospective studies are warranted to determine whether a true clinically important benefit exists with this technique.
This study will test a theory-based intervention to increase levels of exercise among breast cancer survivors, in order to help them self-manage their long-term treatment side effects. The study focuses on outcome expectations (OEs), a significant yet understudied construct that is central to most behavior change theories. OEs refer to what people expect to obtain or avoid by engaging in a behavior; thus, people exercise because they believe it will produce desired outcomes. This randomized controlled trial will test a multicomponent intervention to increase exercise OEs and assess effects of OE changes on exercise intentions and levels of exercise. Sixty early stage (IA to IIB) inactive breast cancer survivors will be recruited from the Duke Cancer Institute. Participants will be randomized to the exercise OE intervention or an attention control group. Both groups will receive the American Cancer Society diet and exercise guidelines and an accelerometer. The intervention group will also receive an OE workbook containing self-directed activities to increase OEs by focusing on OE importance (value placed on the outcome(s)), certainty (perceived probability outcome(s) will occur); and accessibility (frequency with which the outcome(s) are thought of). The attention control group will receive a workbook containing the same activities focused on diet, rather than exercise. OE importance, OE certainty, OE accessibility, exercise intentions, exercise, and self-efficacy (a potential co-variate) will be assessed through online surveys at baseline, 4-, 8-, and 12-weeks post-intervention. At each time point, accelerometer data will be collected as an objective exercise measure. Specific aims of the study are to: (1) examine trajectories of OE importance, certainty and accessibility between participants in the OE intervention arm compared to participants in the attention control arm, across four time points: baseline, 4-, 8- and 12-weeks post-intervention; and (2) examine trajectories of exercise intentions and total weekly minutes of exercise, between participants in the OE intervention arm compared to participants in the attention control arm, across four time points: baseline, 4, 8 and 12 weeks post-intervention. If the intervention increases exercise among breast cancer survivors it may lead to improved survivorship duration and quality of life. The intervention can be implemented readily in clinic settings to support survivors to exercise more and thus experience better long-term outcomes. This study also provides a foundation for a developing a nurse scientist's program of research focused on designing theory-based exercise interventions for chronically ill populations.
A method, system and computer program product are provided. A computing system collects information related to a patient's preparation for a medical procedure and provides information regarding the medical procedure and a medical condition of the patient to at least one member of a medical procedure team. Data pertaining to performance of the medical procedure in an operating room is collected from multiple sensors. Progress of the medical procedure is monitored in real time by analyzing the collected data, a procedure reference library, and a physician history to determine a status of the medical procedure. A schedule of one or more subsequent medical procedures for the operating room is adjusted in real time based on the monitored progress. Notifications of the adjusted schedule may be transmitted to participants of the one or more subsequent medical procedures.
The New Mexico Department of Corrections Recidivism Reduction Program (RRP) is designed to provide offenders with knowledge and skills that are transferable to the community setting and to address issues that offenders will invariably face upon release to the community. Transitional coping skills, offender expectations upon release, family issues, and dealing with authority figures are a few of the challenges facing offenders upon reintegration. The Recidivism Reduction Program is aimed at preparing offenders for the potential obstacles that they may encounter upon release to the community and providing them skills to overcome the challenges that they will face. The RRP curriculum focuses on belief systems, self-esteem, and rational thinking. The RRP is a twenty-one module clinician-led program (approximately 100 hours) delivered in a group setting within months of release. Outcomes focus on measures of transition readiness, successful transition into the community, and recidivism.
Glimepiride tablets should be administered with breakfast or the first main meal of the day.

The recommended starting dose of glimepiride tablets is 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1)and Use in Specific Populations (8.5,8.6)].

After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient’s glycemic response. Uptitration should not occur more frequently than every 1 to 2 weeks. A conservative titration scheme is recommended for patients at increased risk for hypoglycemia [see Warnings and Precautions (5.1)and Use in Specific Populations (8.5, 8.6)].

The maximum recommended dose is 8 mg once daily.

Patients being transferred to glimepiride tablets from longer half-life sulfonylureas (e.g., chlorpropamide) may have overlapping drug effect for 1 to 2 weeks and should be appropriately monitored for hypoglycemia.

When colesevelam is coadministered with glimepiride, maximum plasma concentration and total exposure to glimepiride is reduced. Therefore, glimepiride should be administered at least 4 hours prior to colesevelam.
Cryptosporidium spp. is a diarrhea-causing protozoan. Immunocompromised patients may develop severe and persistent clinical forms. Here we describe the characteristics of patients with an underlying disease associated with immunosuppression (DAI) and Cryptosporidium spp. infection seen at a referral children's hospital in Argentina between 2018 and 2023. Demographic data, DAI, diarrhea characteristics, and co-infections were analyzed. A total of 30 patients with DAI and cryptosporidiosis were included. Most of them had undergone a solid organ transplant, had a hematologic neoplasm, or primary immunodeficiency. Persistent diarrhea was observed in 18 patients at the time of diagnosis. Co-infections were recorded in 6 patients. Cryptosporidiosis should be considered in the differential diagnosis of acute or persistent diarrhea in children with different types of DAI, such as solid organ transplant, hematologic neoplasms, and primary immunodeficiencies.
The invention discloses a method for structural storage of medical information. By the adoption of the method for structural storage of the medical information, structural storage can be conducted on all kinds of complicated information. According to the method for structural storage of the medical information, a table (or a plurality of tables with the same structure) is used for storing all kinds of information. According to a relational database, transverse N fields are used for storing information of an object. According to the method for structural storage of the medical information, longitudinal N records or longitudinal (N+X) records are used for storing information of an object. Various data of any table of the relational database can be stored in the table applied to the method for structural storage of the medical information through conversion. By the adoption of the method for structural storage of the medical information, structurization of the medical information can be effectively achieved. The method for structural storage of the medical information can be achieved in the relational database at present.
Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
The invention relates to a Chinese traditional medicament for curing hyperlipaemia, characterized in that the proportion by weight of the following materials is that astragalus 30.0-60.0, peach kernel 6.0-15.0, safflower 6.0-15.0, fleece-flower root 15.0-30.0, americanwater plantain 10.0-30.0, haw 10.0-30.0, pinellia tuber 6.0-15.0, tangerine peel 6.0-15.0, tuckahoe 10.0-30.0, liquorice 3.0-10.0,bamboo shavings 6.0-20.0, and immature bitter orange 6.0-20.0. Towards the combined hypertension, the medicament can be charged with gastrodia elata 10.0-15.0, uncaria 10.0-30.0, abalone shell 20.0-30.0, and achyranthes 10.0-20.0. Towards the combined blood hyperviscosity syndrome, the medicament can be charged with earthworm 10.0-20.0 and bloodsucker 3.0-9.0. Towards the combined fatty liver, the medicament can be charged with polygonum cuspistum 10.0-20.0 and cassia tora 10.0-20.0. The invention has good curative effect, short period of treatment, low charge and small side effect through the clinical application, applicable to various diseases induced by hyperlipaemia. The observed result of the clinical curative effect of the invention which is used in Chinese traditional medicament hospital in Chencang District, Baoji City, Shanxi Province shows that the cure rate is 70.5%, and the total effective rate is 98.4%.
The present invention concerns a system (1) for assisting the conduct of programmed activities. The system (1) comprises: a wearable electronic device (2), wearable by a user, comprising a sound reproduction module (32) and an interactive portion (13, 31 ) configured to detect a touch of the user, and a software application (4) running on a remote terminal (5) suitable for exchanging data with the wearable electronic device (2). In particular, the software application (4) comprises an agenda (70) that stores at least one voice message, said voice message comprising an invitation to carry out an activity and is associated with a time instant, the software application (4) being configured to transmit the at least one voice message and the time instant associated therewith to the wearable electronic device (2). In addition, the wearable electronic device (2) is configured to reproduce the at least one voice message at the time instant associated with the at least one voice message. Advantageously, the wearable electronic device (2) is further configured to detect at least one touch of the interactive portion (13, 31) following the reproduction of the at least one voice message, measure a duration of the at least one touch, transmit a number of detected touches and the measured duration of each detected touch. In addition, the software application (4) is configured to identify a vexing event experienced by the user when it is detected at least one between a touch lasting longer than a threshold duration value, and a sequence of consecutive touches within a predetermined time interval.